A5010990321- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Hemophilia Treatment and Research
- Hemoglobinopathies and Related Disorders
- Cytokine Signaling Pathways and Interactions
- Blood Coagulation and Thrombosis Mechanisms
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Kruppel-like factors research
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Histone Deacetylase Inhibitors Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Advanced Breast Cancer Therapies
- Erythrocyte Function and Pathophysiology
- Hematological disorders and diagnostics
- Immunotherapy and Immune Responses
- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Parvovirus B19 Infection Studies
University Hospital St. Marina
2015-2025
Acibadem City Clinic
2021
Tokuda Hospital
2021
Medical University of Varna
2006-2019
Palmetto Hematology Oncology
2019
Menlo School
2019
Linde (United States)
2017
National Institute of Emergency Medicine "Pirogov"
2012
University Specialized Hospital for Active Treatment of Endocrinology
2009-2010
This randomized, open-label, parallel-group, multicenter study was designed to compare the efficacy and safety of bendamustine chlorambucil in previously untreated patients with advanced (Binet stage B or C) chronic lymphocytic leukemia (CLL).Patients (<or= 75 years age) were randomly assigned receive 100 mg/m(2)/d intravenously on days 1 2, 0.8 mg/kg (Broca's normal weight) orally 15; treatment cycles repeated every 4 weeks for a maximum six cycles. The response assessed according National...
Current hemophilia treatment involves frequent intravenous infusions of clotting factors, which is associated with variable hemostatic protection, a high burden, and risk the development inhibitory alloantibodies. Fitusiran, an investigational RNA interference (RNAi) therapy that targets antithrombin (encoded by SERPINC1), in to address these other limitations.
Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of units transfused) in such patients.
Erythropoiesis-stimulating agents are first choice for treating anemia in low-risk MDS. This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, no moderate RBC transfusion dependence (≤4 units/8 weeks). Patients were randomized, 2:1, to receive 450 IU/kg/week placebo 24 weeks, followed by treatment extension responders. The primary endpoint was erythroid response (ER) through...
We compared the safety and efficacy of siltuximab (S), an anti‐interleukin‐6 chimeric monoclonal antibody, plus bortezomib (B) with placebo (plc) + B in patients relapsed/refractory multiple myeloma a randomized phase 2 study. Siltuximab was given by 6 mg/kg IV every weeks. On progression, discontinued high‐dose dexamethasone could be added to S/plc. Response progression‐free survival (PFS) were analyzed pre‐dexamethasone European Group for Blood Marrow Transplantation (EBMT) criteria. For...
Essentials High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthropathy. SPINART was a 3-year randomized clinical trial late/tertiary vs on-demand therapy. Prophylaxis improved function, quality life, activity pain but not joint structure by MRI. improves function must start before bleeding onset to prevent arthropathy.Background Limited exist the impact severe A pre-existing disease. Objectives To describe bleeding, health structure, health-related...
Fitusiran, an investigational small interfering RNA therapy, reduces antithrombin production to rebalance hemostasis in people with hemophilia A or B, without inhibitors.To evaluate the safety and efficacy of fitusiran treatment for moderate/severe B inhibitors.In this open-label phase 1, part D study, 17 males inhibitors received three once-monthly subcutaneous injections 50 mg (n = 6) 80 11); followed up 112 days. Endpoints included (primary), pharmacokinetics/pharmacodynamics (secondary),...
Summary The efficacy of bendamustine versus chlorambucil in a phase III trial previously untreated patients with B inet stage B/C chronic lymphocytic leukaemia ( CLL ) was re‐evaluated after median observation time 54 months M ay 2010. Overall survival OS analysed for the first time. At follow‐up, investigator‐assessed complete response CR rate (21·0% vs 10·8%), progression‐free (21·2 8·8 months; P < 0·0001; hazard ratio 2·83) and to next treatment (31·7 10·1 0·0001) were improved over...
Introduction Nuwiq ® (human‐cl rh FVIII ) is a 4 th generation recombinant human , without chemical modification or protein fusion, produced in cell‐line. Aims/Methods This study (NuPreviq) was prospective, open‐label, multicentre, phase III b of the efficacy and safety personalized prophylaxis with 66 previously treated adults severe haemophilia A. NuPreviq had three phases: (i) 72‐h pharmacokinetic ( PK phase; (ii) 1–3 month standard (iii) 6‐month phase. The regimen based on individual...
This phase 3 study evaluated the efficacy and safety of new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n 407) azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia unfit to receive intensive induction chemotherapy. Half (50%) had poor Eastern Cooperative Oncology Group Performance Status (2-3). The coprimary end points were complete remission (19% 17% for TC, respectively [stratified P .48]) overall survival (median...
Summary Head‐on comparative studies of factor IX (FIX) concentrates performed under standardized conditions are rarely conducted regardless being a valuable instrument guiding health care providers towards better informed and cost‐effective decisions. This study is an extension multicentre that assessed the efficacy, safety pharmacokinetics ( PK ) AlphaNine ® in 25 previously treated patients with severe haemophilia B (FIX:C ≤ 2%). After washout period ≥7 days following last after dose 65–75...
Background Imatinib 400 mg/day is the standard treatment for patients with chronic phase myeloid leukemia. Recent reports suggested higher and more rapid cytogenetic molecular responses doses of imatinib.Design Methods In this prospective international, multicenter III study, 227 pre-treated Philadelphia chromosome-positive, BCR-ABL-positive leukemia were randomized to a standard-dose imatinib arm (400 mg/day) or high-dose (800 6 months followed by as maintenance therapy). planned interim...
Summary. Effective treatment with factor IX (FIX) requires a thorough consideration of the properties concentrate to be used as replacement therapy, date, only available for haemophilia B. The aim study was determine pharmacokinetics, clinical efficacy and safety in routine use AlphaNine®, high-purity human FIX concentrate. This open, single-arm, multicentre, non-randomized trial included 25 subjects (age ≥ 12) moderate/severe Pharmacokinetics assessed at baseline after 6-month follow-up....
8018^ Background: Preclinical studies of siltuximab (S), a chimeric anti-IL-6 mAb, in combination with bortezomib (B) indicate an additive to synergistic effect multiple myeloma (MM) cell lines. This randomized study evaluated the safety and efficacy S+B compared placebo (plc)+B pts relapsed/refractory MM after 1−3 prior tx lines, measurable disease but no B exposure. Methods: 286 were 1:1 S+B: B+plc. S 6 mg/kg or plc was given IV q2w. 1.3 mg/m 2 on d 1, 4, 8, 11, 22, 25, 29, 32 for max 4...